[1]吴 涛,苗 牛,张明勤,等.mRNA-527与经肝动脉化疗栓塞术治疗肝细胞癌预后的关系[J].介入放射学杂志,2021,30(03):239-243.
 WU Tao,MIAO Niu,ZHANG Mingqin,et al.Correlation between microRNA-527 level and the prognosis in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization treatment[J].journal interventional radiology,2021,30(03):239-243.
点击复制

mRNA-527与经肝动脉化疗栓塞术治疗肝细胞癌预后的关系()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年03
页码:
239-243
栏目:
肿瘤介入
出版日期:
2021-03-29

文章信息/Info

Title:
Correlation between microRNA-527 level and the prognosis in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization treatment
作者:
吴 涛 苗 牛 张明勤 刘阳阳 杨冬谊
Author(s):
WU Tao MIAO Niu ZHANG Mingqin LIU Yangyang YANG Dongyi.
Department of Intervention, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province 450000, China
关键词:
【关键词】 肝细胞肝癌 经肝动脉化疗栓塞术 微RNA-527预后
文献标志码:
A
摘要:
【摘要】 目的 探究miR-527与TACE治疗肝细胞癌(HCC)预后的关系。方法 前瞻性选取2015年3月至2017年4月在河南中医药大学第一附属医院就诊的168例HCC患者作为研究对象。采用实时荧光定量PCR法检测HCC患者血浆中miR-527水平。用Cox回归和限制性立方样条分析miR-527与HCC预后的关系。结果 3年后生存组(114例)术后miR-527水平高于死亡组(54例),差异有统计学意义(P<0.05)。术后miR-527诊断HCC患者预后的受试者工作特征(ROC)曲线下面积(AUC)、灵敏度和特异度分别为0.839(95%CI:0.775~0.891)、74.07%和84.21%,其诊断效能高于术前miR-527,差异有统计学意义(P<0.05)。Cox回归分析结果显示肿瘤分期是HCC患者预后的独立危险因素(P<0.05),索拉非尼和miR-527是HCC患者预后的独立保护因素(P<0.05)。miR-527与HCC患者预后有关(P<0.05),且呈线性关系(非线性检验P>0.05)。当miR-527<1.60时,与miR-527=1.60比较,预后不良风险高;当miR-527>1.60时,与miR-527=1.60比较,预后不良风险低。结论 TACE术后miR-527水平与HCC患者预后有关,其水平低提示预后不良风险高。

参考文献/References:

[1] Chow PK, Choo SP, Ng DC, et al. National cancer centre Singapore consensus guidelines for hepatocellular carcinoma[J]. Liver Cancer, 2016, 5: 97-106.
[2] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma:trends,risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16: 589-604.
[3] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69: 182-236.
[4] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival[J]. Hepatology, 2003, 37: 429- 442.
[5] 孙伟航,张骜丹,李 巍. 预后营养指数联合磁共振表观扩散系数在肝细胞癌肝动脉化疗栓塞中的临床应用价值[J]. 中华医学杂志, 2019, 99:2581-2585.
[6] Sun HX, Yang ZF, Tang WG, et al. MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma[J]. J Cancer, 2020, 11: 2476-2484.
[7] Liu J, Hou K, Ji H, et al. Overexpression of circular RNA circ-CDC45 facilitates glioma cell progression by sponging miR-516b and miR-527 and predicts an adverse prognosis[J]. J Cell Biochem, 2020, 121: 690-697.
[8] Liu H, Han L, Liu Z, et al. Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway[J]. J Cell Physiol, 2019, 234: 13843-13850.
[9] Huo W, Zhu XM, Pan XY, et al. MicroRNA-527 inhibits TGF-β/SMAD induced epithelial-mesenchymal transition via downre-gulating SULF2 expression in non- small- cell lung cancer[J]. Math Biosci Eng, 2019, 16: 4607-4621.
[10] Alhasan SF, Beale GS, Newell DR, et al. Suppression of SULF2,an extracellular endosulfatase up-regulated in hepatocel lular cancers,modulates WNT signalling and inhibits cell growth[J]. Gut, 2012, 61(Suppl 2):A111-A112.
[11] Hu JL, Wang W, Lan XL, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer[J]. Mol Cancer, 2019, 18: 91.
[12] Ko YS, Jin H, Lee JS, et al. Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells[J]. Oncol Rep, 2018, 40: 3752-3762.
[13] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作委员会, 中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治专家共识[J]. 临床肿瘤学杂志, 2009, 14:259-269.
[14] 中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 中华医学杂志, 2018, 98:3811-3819.
[15] Li W, Chen Z, Cai C, et al. MicroRNA-505 is involved in the regulation of osteogenic differentiation of MC3T3- E1 cells partially by targeting RUNX2[J]. J Orthop Surg Res, 2020, 15: 143.
[16] 刘璐璐,赵慧金,李胜棉. 肝细胞癌组织microRNA-187-3p表达预后意义[J]. 中华肿瘤防治杂志, 2017, 24:1059-1064.
[17] Cui Y, Xu HF, Liu MY, et al. Mechanism of exosomal microRNA-224 in development of hepatocellular carcinoma and its diagnostic and prognostic value[J]. World J Gastroenterol, 2019, 25: 1890-1898.
[18] Chen P, Li X, Zhang R, et al. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation[J]. Theranostics, 2020, 10: 5107-5119.
[19] 褚 亚,周 石,王黎洲,等. 磷脂酶Cβ1上调表达与肝细胞肝癌增殖和预后相关[J]. 介入放射学杂志, 2018, 27:29-34.
[20] 武正山,刘一纬,吴晓峰. 肝癌组织CCR1表达与患者预后的关系[J]. 南京医科大学学报(自然科学版), 2019, 39: 1737-1740.
[21] 郑家平,邵国良,罗 君,等. 索拉非尼治疗中晚期肝细胞癌安全性和预后因素分析[J]. 介入放射学杂志, 2014, 23:222-225.
[22] Huo T, Liu PH, Hsu CY. Staging and restaging for hepatocellular carcinoma: solution of confusion?[J]. Hepatology, 2019, 69: 464-465.

相似文献/References:

[1]何伟华,独建库,邹 洋,等.TACE联合瘤体注射热碘油治疗大肝癌[J].介入放射学杂志,2014,(09):777.
 HE Wei hua,DU Jian ku,ZOU Yang,et al.TACE combined with injection of hyper thermic lipiodol into tumor body for the treatment of large hepatic carcinoma[J].journal interventional radiology,2014,(03):777.
[2]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
 YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history: initial experience in seven cases[J].journal interventional radiology,2014,(03):805.
[3]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
 XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib: initial experience in 23 cases[J].journal interventional radiology,2014,(03):449.
[4]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
 ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma: analysis of the prognosis and survival[J].journal interventional radiology,2014,(03):435.
[5]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
 WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus: a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(03):419.
[6]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
 YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure: report of three cases[J].journal interventional radiology,2016,(03):381.
[7]姚 征,陈玉堂,罗 君,等.131I美妥昔单抗注射液联合TACE治疗76例中晚期原发性肝癌的疗效及安全性研究[J].介入放射学杂志,2016,(01):65.
 YAO Zheng,CHEN Yu- tang,LUO Jun,et al.131I- labeled metuximab combined with transcatheter arterial chemoembolization for advanced primary hepatic carcinomas: evaluation of safety and effect in 76 patients[J].journal interventional radiology,2016,(03):65.
[8]许 贇,沈 强,王 能,等.微波消融治疗>70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
 XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(03):332.
[9]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
 WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC: initial results in 7 patients[J].journal interventional radiology,2017,(03):161.
[10]王 燕,王茂强,段 峰.索拉非尼治疗中晚期肝癌预后因素分析[J].介入放射学杂志,2017,(03):258.
 WANG Yan,WANG Maoqiang,DUAN Feng.Prognostic factor analysis of moderate- advanced hepatocellular carcinoma treated with sorafenib [J].journal interventional radiology,2017,(03):258.
[11]吴 军,闫雪华,陈小勇,等.金属硫蛋白-3与肝细胞肝癌 TACE治疗近、远期疗效的关系[J].介入放射学杂志,2021,30(02):168.
 WU Jun,YAN Xuehua,CHEN Xiaoyong,et al.The relationship of metallothionein-3 level to the short-term and long-term efficacy of TACE therapy for hepatocellular carcinoma[J].journal interventional radiology,2021,30(03):168.

备注/Memo

备注/Memo:
(收稿日期:2020-04-27)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-03-24